Management of neurocysticercosis
- PMID: 20406600
- DOI: 10.1179/016164110X12644252260592
Management of neurocysticercosis
Abstract
Background: Neurocysticercosis is a parasitic infection of the central nervous system caused by the larval stage of the tapeworm Taenia solium and is the most common parasitic infection involving the human nervous system. Neurocysticercosis represents one of the most common causes of symptomatic epilepsy in developing countries and is an increasing concern in industrialized nations.
Methods: We conducted a review of the medical literature regarding the current management of neurocysticercosis in Latin American countries.
Results: Mexico and Brazil report the highest incidence of neurocysticercosis in Latin America. However, major obstacles interfere with an accurate determination of the prevalence of neurocysticercosis, including the lack of standardized and comprehensive epidemiological systems, intrinsic limitations of current immunological studies, the high cost of neuroimaging studies in rural communities and the presence of asymptomatic patients with neuroimaging characteristic compatible with neurocysticercosis. As such, the real prevalence of the disease and its burden are likely underestimated in Latin America. There is no universal consensus or guidelines for the management of different forms of the disease, but most experts agree in the use of antihelminithic therapy when viable cysts are encountered and with the use of corticosteroids in patients presenting with encephalitis.
Discussion: Neurocysticercosis is a pleomorphic disease, with a broad spectrum of clinical and radiographic features. The medical management of neurocysticercosis is complex and needs to be individualized.
Similar articles
-
Advances in the diagnosis and management of neurocysticercosis.Expert Rev Anti Infect Ther. 2006 Dec;4(6):1051-61. doi: 10.1586/14787210.4.6.1051. Expert Rev Anti Infect Ther. 2006. PMID: 17181420 Review.
-
Neurocysticerosis: An Individualized Approach.Infect Dis Clin North Am. 2019 Mar;33(1):153-168. doi: 10.1016/j.idc.2018.10.007. Infect Dis Clin North Am. 2019. PMID: 30712759 Review.
-
[Neurocysticercosis].Rev Neurol. 1999 Sep 1-15;29(5):456-66. Rev Neurol. 1999. PMID: 10584250 Review. Spanish.
-
Neurocysticercosis.Handb Clin Neurol. 2014;121:1445-59. doi: 10.1016/B978-0-7020-4088-7.00097-3. Handb Clin Neurol. 2014. PMID: 24365429 Review.
-
[Paediatric neurocysticercosis: two case reports].Rev Neurol. 2013 Jan 16;56(2):86-90. Rev Neurol. 2013. PMID: 23307354 Spanish.
Cited by
-
Cranial hypertrophic pachymeningitis secondary to neurocysticercosis.Neurol Sci. 2013 Mar;34(3):401-3. doi: 10.1007/s10072-012-1002-4. Epub 2012 Mar 9. Neurol Sci. 2013. PMID: 22402790
-
A dot-ELISA using a partially purified cathepsin-L-like protein fraction from Taenia solium cysticerci, for the diagnosis of human neurocysticercosis.Ann Trop Med Parasitol. 2011 Jun;105(4):311-8. doi: 10.1179/136485911X12987676649782. Ann Trop Med Parasitol. 2011. PMID: 21871167 Free PMC article.
-
Clinical manifestations, diagnosis, and treatment of neurocysticercosis.Curr Neurol Neurosci Rep. 2011 Dec;11(6):529-35. doi: 10.1007/s11910-011-0226-7. Curr Neurol Neurosci Rep. 2011. PMID: 21915772 Review.
-
Topographic congruence of calcified parenchymal neurocysticercosis and other structural brain lesions with epileptiform activity.Trop Parasitol. 2016 Jan-Jun;6(1):51-5. doi: 10.4103/2229-5070.175093. Trop Parasitol. 2016. PMID: 26998434 Free PMC article.
-
Giant Neurocysticercosis: A Rare Medical Condition.Cureus. 2024 Oct 8;16(10):e71090. doi: 10.7759/cureus.71090. eCollection 2024 Oct. Cureus. 2024. PMID: 39386929 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials